Literature DB >> 9803675

Induction of antitumor cytotoxic activity using CD34+ cord blood cell-derived and irradiated tumor cell-primed dendritic cells.

S Fujii1, K Fujimoto, M Osato, K Matsui, K Takatsuki, M Kawakita.   

Abstract

Dendritic cells (DCs) are the most powerful antigen-presenting cells in the immune system. They can activate immunologically naive T cells and improve the efficacy of immunotherapy against tumors. In the present study we investigated whether CD34+ cord blood cell-derived DCs are capable of inducing antitumor cytotoxic cells, such as cytotoxic T lymphocytes (CTLs), NK cells, and monocytes. Cord blood T cells stimulated by DCs pulsed with irradiated K562 major histocompatibility complex (MHC) class I+ cells were highly effective in eliciting a selective killing response against K562 class I+ cells. This killing activity was almost completely abrogated by antibodies to CD8 or MHC class I, but not to CD4. This suggests that tumor cell-pulsed DCs generated from CD34+ cord blood cells are able to induce tumor specific CTLs against corresponding tumor cells from cord blood T cells, and that these CTLs are CD8+ T cells which may recognize tumor cells via MHC class I molecules. This observation has potentially important implications for the use of DCs in clinical immunotherapy in cord blood transplantation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9803675     DOI: 10.1016/s0925-5710(98)00069-3

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  4 in total

Review 1.  Vaccines as consolidation therapy for myeloid leukemia.

Authors:  Gheath Alatrash; Jeffrey J Molldrem
Journal:  Expert Rev Hematol       Date:  2011-02       Impact factor: 2.929

2.  Ex vivo expansion of CD34+ and T and NK cells from umbilical cord blood for leukemic BALB/C nude mouse transplantation.

Authors:  Yaming Wei; Yinfeng Huang; Yinze Zhang; Huayou Zhou; Qiong Cao; Qingbao Meng; Juncai Lan; Longhua Chen
Journal:  Int J Hematol       Date:  2008-02-08       Impact factor: 2.490

3.  Analysis of a chronic myelogenous leukemia patient vaccinated with leukemic dendritic cells following autologous peripheral blood stem cell transplantation.

Authors:  S Fujii; K Shimizu; K Fujimoto; T Kiyokawa; T Shimomura; M Kinoshita; F Kawano
Journal:  Jpn J Cancer Res       Date:  1999-10

4.  Umbilical cord blood-derived CD11c(+) dendritic cells could serve as an alternative allogeneic source of dendritic cells for cancer immunotherapy.

Authors:  Jeetendra Kumar; Vaijayanti Kale; Lalita Limaye
Journal:  Stem Cell Res Ther       Date:  2015-09-25       Impact factor: 6.832

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.